Contact Us

Please visit our Patient Support page if you are a patient or caregiver looking for more information about Horizon's patient support program, Horizon By Your Side. This program is available for eligible U.S residents only.

In the U.S., to request medical information, please call 1-866-479-6742 (Option 1). If you are a U.S. health care professional looking for medical information, please visit our Medical Resources page.

 If you are located outside the U.S., please use the relevant contact information below:

• Austria: call 0800 909 200 or email medicalinformationEU@horizontherapeutics.com
• Brazil: call 0800 761 0186 or email medicalinformationBR@horizontherapeutics.com
• Canada: call 1-866-479-6742 (Option 1) or email medicalinformation@horizontherapeutics.com
• Germany: call 0800 4 500006 or email medicalinformationEU@horizontherapeutics.com
• Italy: call 80 097 172 6 or email medicalinformationEU@horizontherapeutics.com
• Saudi Arabia: email Safety_KSA@horizontherapeutics.com
• Spain: call 90 0816 508 or email medicalinformationEU@horizontherapeutics.com

In the U.S., to report an adverse event/side effect or quality complaint related to any Horizon medicine, please call 1-866-479-6742 (Option 1).

In Canada, to report an adverse event/side effect or quality complaint related to any Horizon medicine, please call TranscendRare™ at 1-844-380-7850 (Monday to Friday 8 a.m. – 8 p.m. EST) or call 1-866-479-6742 (Option 1).

If you are located outside the U.S. or Canada, to report an adverse event/side effect or quality complaint related to any Horizon medicine, please use the relevant contact information below:

• Austria: call 0800 909 200
• Brazil: call 0800 761 0186
• Germany: call 0800 4 500006
• Italy: call 80 097 172 6
• Saudi Arabia: email Safety_KSA@horizontherapeutics.com
• Spain: call 90 0816 508

Amgen recently acquired Horizon Therapeutics. For more information about clinical trials involving Horizon medicines and experimental treatments, click here.

For questions about Horizon clinical trials call 1-866-479-6742 or email clinicaltrials@horizontherapeutics.com.

To find more information about our Named Patient Use Programs, please visit the following pages:

• Named Patient Use Program for TEPEZZA® (teprotumumab-trbw)
• Named Patient Use Program for UPLIZNA® (inebilizumab-cdon)

See Amgen business development contact information on amgenbd.com.

See Amgen investor contact information on investors.amgen.com.

See Amgen media contact information on amgen.com.

Canada